MCRB
Seres Therapeutics, Inc.
There isn't enough reported data to score MCRB yet.
MCRB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
MCRB's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
MCRB PE Valuation
MCRB has no meaningful PE right now: it lost money over the past year.
MCRB Forward outlook
There aren't enough analyst estimates for MCRB to show an outlook.
MCRB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.02 | -910% |
| Q2 2026 | -$2.45 | -122% |
| Q1 2026 | -$5.19 | -157% |
| Q4 2025 | $0.64 | +$0.64 |
| Q3 2025 | $0.62 | +$5.02 |
| Q2 2025 | $11.28 | +$34.68 |
| Q1 2025 | $9.15 | +$20.95 |
| Q4 2024 | $0.00 | +$17.71 |
MCRB has swung to a loss: it lost $5.02 per share over the past year, after a profit the year before.
MCRB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $593K | +69% |
| Q4 2023 | $64K | -93% |
| Q3 2023 | $310K | -91% |
| Q2 2023 | $126.5M | +10301% |
| Q4 2022 | $975K | -86% |
| Q3 2022 | $3.4M | -97% |
| Q2 2022 | $1.2M | -77% |
| Q1 2022 | $1.5M | -74% |
MCRB's revenue is recovering but still below its 2021 peak: $593,000 last quarter, up 69% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -2724% | +3680 points |
| Q2 2026 | -2890% | N/A |
| Q1 2026 | -5840% | N/A |
| Q4 2025 | -4424% | N/A |
| Q3 2025 | -6404% | N/A |
| Q4 2023 | -61759% | -54754 points |
| Q3 2023 | -15295% | -13578 points |
| Q2 2023 | 39% | +5247 points |
MCRB's operating margin was −2724% last quarter, up 3680 points from the same quarter a year ago.
MCRB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.5M | -577% |
| Q2 2026 | -$22.4M | -$8.9M |
| Q1 2026 | -$16.4M | -161% |
| Q4 2025 | -$14.7M | +$24.2M |
| Q3 2025 | $2.2M | +$37M |
| Q2 2025 | -$13.5M | +$26.4M |
| Q1 2025 | $26.9M | +$62.2M |
| Q4 2024 | -$39M | +$9.4M |
MCRB has burned cash in almost every quarter: −$64M over the past year, against −$23M the year before.
MCRB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.4% | +235K shares |
| 1 year | +14% | +1.2M shares |
| 3 years | +56% | +3.6M shares |
| 5 years | +110% | +5.2M shares |
| Available history | +182% | +6.4M shares |
MCRB has 10M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2023 | — |
MCRB Net Leverage
MCRB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MCRB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.5 | Oversold |
| Stochastic | 3.9 | Oversold |
MCRB's weekly RSI is 25 (oversold) and its Stochastic is 4 (oversold).
MCRB PE vs Healthcare Sector
| Metric | MCRB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MCRB has no meaningful PE right now: it lost money over the past year.
MCRB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.36 | 40% below |
| 20 week MA | $4.08 | 65% below |
| 50 week MA | $7.91 | 82% below |
| 100 week MA | $11.2 | 87% below |
| 200 week MA | $29.8 | 95% below |
MCRB is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
MCRB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $80.0 | $485.6 | +507% |
| 2021 | $485.6 | $183.4 | -62% |
| 2022 | $183.4 | $104.8 | -43% |
| 2023 | $104.8 | $28.0 | -73% |
| 2024 | $28.0 | $17.7 | -37% |
| 2025 | $17.7 | $14.7 | -17% |
| 2026 YTD | $14.7 | $1.41 | -90% |
MCRB has finished five years in a row lower, and it's down 90% so far in 2026.